LYTGOBI®
(futibatinib)
DKSH
HK Reg. No. HK-68839 (04 Sep, 2025)
Composition:4
• Each film-coated tablet contains 4 mg of futibatinib
Indication:4
• Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy
References
4. EMA. Lytgobi Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/lytgobiepar-product-information_en.pdf. [Accessed 18 September 2025].
